AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Phosphatidylcholine:ceramide cholinephosphotransferase 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q86VZ5

UPID:

SMS1_HUMAN

Alternative names:

Medulla oblongata-derived protein; Sphingomyelin synthase 1; Transmembrane protein 23

Alternative UPACC:

Q86VZ5; D3DWC4; Q68U43; Q6EKK0; Q75SP1

Background:

Phosphatidylcholine:ceramide cholinephosphotransferase 1, also known as Sphingomyelin synthase 1, plays a pivotal role at the Golgi apparatus. It catalyzes the reversible transfer of phosphocholine in sphingomyelin biosynthesis, influencing the balance between ceramide, sphingomyelin, and diacylglycerol. This balance is crucial for cell signaling, including mitogenic and proapoptotic pathways, and for the structural integrity of membrane rafts, which are essential for signal transduction and protein sorting.

Therapeutic significance:

Understanding the role of Phosphatidylcholine:ceramide cholinephosphotransferase 1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.